Anti-Venom Drugs Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)

Anti-Venom Drugs Market – Report Overview

Pacific Business Consulting’s “Anti-Venom Drugs Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of Anti-Venom Drugs market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

In 2022, the Anti-Venom Drugs market surpassed a valuation of US$ 2.2 Billion and is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) exceeding 7.0% from 2023 to 2030. The market is anticipated to potentially surpass US$ 4.0 Billion by 2030.

The growth of the Anti-Venom Drugs market can be attributed to several factors. One significant driver is the increasing awareness of available anti-venoms, coupled with a surge in cases of venomous bites. The prevalence of snakebites, often a neglected public health issue in tropical and subtropical countries, has prompted a higher demand for anti-venom drugs. According to the World Health Organization (WHO), approximately 5.4 million snakebites occur each year, leading to 2.7 million envenomings and 81,000 to 138,000 deaths. The growing incidence of snakebites, particularly in countries like India, contributes to the increasing demand for anti-venom treatment.

The COVID-19 pandemic has also played a role in shaping the market dynamics. The pandemic resulted in a considerable increase in deaths from snakebites in some regions, creating a significant need for anti-venoms. However, the pandemic’s impact on already vulnerable health systems led to a treatment gap for snakebites. Post-pandemic, emerging strains of the SARS-CoV-2 virus have been found to have potential interactions with snake venom phospholipases A2, augmenting the demand for anti-venoms among COVID-19 patients.

Initiatives such as partnerships between countries to donate anti-venom drugs and advancements in research, proving the efficacy of existing treatments, are contributing to market growth. For instance, a partnership between Papua New Guinea and Australia extended the donation of anti-venom to save lives from venomous snakes and marine creatures. Additionally, research activities demonstrating the positive results of Indian polyvalent anti-venoms in preventing or reversing in vitro myotoxicity induced by common cobra venom contribute to the market’s expansion.

Polyvalent anti-venoms, which contain antibodies counteracting several homologous venoms, are gaining preference due to their ability to address envenomations from various snake species. Research and development activities validating the efficacy of existing treatments, such as polyvalent anti-venoms, are expected to drive the segment’s growth further.

Increasing awareness, research programs on antidotes, and initiatives by major companies and governments are anticipated to boost the market. For example, WHO-led virtual training workshops on coordinated antidote procurement aim to secure the supply of essential antidotes for poisoning emergencies.

Moreover, the rising incidence of occupational poisoning globally, including pesticide poisoning among farmers, and the prevalence of drug overdoses contribute to the market’s growth. Occupational poisoning and drug overdoses necessitate antidote treatments, leading to increased market demand.

Key players in the Anti-Venom Drugs segment, including pharmaceutical companies and organizations involved in antidote research, are expected to play a crucial role in shaping the future landscape of Anti-Venom Drugs technologies through ongoing innovation.

Key players in the Anti-Venom Drugs segment, including Merck KGaA (Sigma Aldrich), Boehringer Ingelheim, and CSL Limited, BTG PLC, Pfizer Inc., and Ophirex, Inc, are expected to play a crucial role in shaping the future landscape of Anti-Venom Drugs technologies through ongoing innovation.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Anti-Venom Drugs market. It also delves into the analysis of present and prospective market competition within the global Anti-Venom Drugs market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Anti-Venom Drugs market across the 10MM (Ten Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM Anti-Venom Drugs market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

1. Executive Summary: Anti-Venom Drugs
   • Global Market Outlook: Anti-Venom Drugs
2. Competitive Intelligence Analysis: Anti-Venom Drugs
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Anti-Venom Drugs
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Key Marketed Products Profile – Major Approved Products: Anti-Venom Drugs
   • Product Profile
   • Safety and Efficacy
7. Regulatory Landscape
8. Anti-Venom Drugs: Ten Major Market (10MM) – Market Analysis, By Product Type
   • Polyvalent Anti-Venoms
   • Monovalent Anti-Venom
   • Other Anti-Venom Types
9. Anti-Venom Drugs: Ten Major Market (10MM) – Market Analysis, By Species
   • Snakes
   • Scorpions
   • Spiders
   • Other Species
10. Anti-Venom Drugs: Ten Major Market (10MM) – Market Analysis, By End User
    • Hospitals Pharmacies
    • Emergency Care Services
    • Others
11. Anti-Venom Drugs: Ten Major Market (10MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

12. S. Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

13. K. Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

14. Germany Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

15. France Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

16. Italy Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

17. Spain Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

18. Japan Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

19. China Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

20. Australia Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

21. India Anti-Venom Drugs – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product Type
      • By End User
      • By Species
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product Type
      • By End User
      • By Species

22. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

23. Assumptions and Acronyms Used
24. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
25. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, China, Australia, and India
26. Copyrights and Disclaimer